US biotech company Gilead has filed a new revocation action with the UPC targeting a patent owned by the Chinese Academy of Military Medical Sciences. The patent could potentially disrupt sales of
As a lethal coronavirus triggers a humanitarian crisis in the world’s most populous nation, who owns the rights to a potential cure? The Bay Area’s pharmaceutical powerhouse Gilead Sciences is first
Jan 15 (Reuters) - Gilead Sciences (GILD.O) and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday
total 1 pages, 3 items